{"id":391343,"date":"2015-08-26T00:00:00","date_gmt":"2015-08-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0215-biopharma-market-access-opportunities-and-challenges-in-rheumatoid-arthritis-physician-payer-forum-eu5\/"},"modified":"2026-04-22T23:30:23","modified_gmt":"2026-04-22T23:30:23","slug":"pforeu0215-biopharma-market-access-opportunities-and-challenges-in-rheumatoid-arthritis-physician-payer-forum-eu5","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0215-biopharma-market-access-opportunities-and-challenges-in-rheumatoid-arthritis-physician-payer-forum-eu5\/","title":{"rendered":"Market Access Opportunities and Challenges in Rheumatoid Arthritis | Physician &#038; Payer Forum | EU5 | 2015"},"content":{"rendered":"<p><em>A Survey of Rheumatologists and Interviews with Payers in the EU5 <\/em><\/p>\n<p>Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that may result in permanent, debilitating tissue damage. Early intervention with disease-modifying antirheumatic drugs (DMARDs), both conventional and biological, can effectively treat the symptoms of RA and slow joint destruction. However, high-cost biological therapy is typically initiated, with TNF-\u03b1 inhibitors, in patients who have failed therapy with conventional DMARDs. The non-TNF-\u03b1 inhibitor biologics (e.g., MabThera [Roche\u2019s rituximab], Orencia [Bristol-Myers Squibb\u2019s abatacept], RoActemra [Roche\u2019s tocilizumab]) largely compete for use in the TNF-refractory population. The launch of biosimilar versions of Remicade (Janssen\u2019s infliximab) in the EU5 markets in early 2015, and the anticipated arrival over the next few years of biosimilars for the leading RA biologics, Enbrel (Pfizer\u2019s etanercept) and Humira (AbbVie\u2019s adalimumab), will drastically change the dynamics in this high-priced market. In the increasingly crowded and intensely competitive RA market, emerging RA agents will face rigorous HTA and P&#038;R negotiations as payers and physicians aim to balance clinical efficacy with budgetary constraints. This report analyzes European rheumatologists\u2019 and payers\u2019 expectations and attitudes regarding the changing RA market through year-end 2018.<\/p>\n","protected":false},"template":"","class_list":["post-391343","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391343\/revisions"}],"predecessor-version":[{"id":576944,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391343\/revisions\/576944"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}